RTC
ABBV icon

Riverview Trust Company’s AbbVie ABBV Stock Holding History

Riverview Trust Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$694K Hold
3,193
– – 0.86% 21
2025
Q4 		$730K Hold
3,193
– – 0.88% 18
2025
Q3 		$739K Hold
3,193
– – 0.89% 20
2025
Q2 		$593K Sell
3,193
-3,013
-49% -$560K 0.74% 21
2025
Q1 		$1.3M Sell
6,206
-1,093
-15% -$212K 1.28% 14
2024
Q4 		$1.3M Sell
7,299
-45
-0.6% -$8.27K 1.18% 18
2024
Q3 		$1.45M Buy
7,344
+30
+0.4% +$5.6K 1.27% 16
2024
Q2 		$1.25M Sell
7,314
-360
-5% -$59.6K 1.19% 19
2024
Q1 		$1.4M Hold
7,674
– – 1.08% 18
2023
Q4 		$1.19M Buy
7,674
+39
+0.5% +$5.69K 1.21% 21
2023
Q3 		$1.14M Hold
7,635
– – 1.01% 21
2023
Q2 		$1.03M Sell
7,635
-180
-2% -$26.4K 0.93% 21
2023
Q1 		$1.25M Hold
7,815
– – 1.14% 18
2022
Q4 		$1.26M Sell
7,815
-183
-2% -$28.1K 1.2% 15
2022
Q3 		$1.07M Sell
7,998
-189
-2% -$27.1K 1.04% 16
2022
Q2 		$1.25M Buy
8,187
+249
+3% +$38K 1.09% 18
2022
Q1 		$1.29M Buy
7,938
+786
+11% +$114K 0.95% 19
2021
Q4 		$968 Buy
7,152
+726
+11% +$85.8K 0.57% 26
2021
Q3 		$693K Buy
6,426
+756
+13% +$86.4K 0.73% 30
2021
Q2 		$639K Sell
5,670
-320
-5% -$36K 0.68% 31
2021
Q1 		$648K Hold
5,990
– – 0.72% 30
2020
Q4 		$642K Sell
5,990
-125
-2% -$12K 0.71% 30
2020
Q3 		$536K Sell
6,115
-45
-0.7% -$4.24K 0.62% 34
2020
Q2 		$605K Sell
6,160
-320
-5% -$28.2K 0.59% 33
2020
Q1 		$494K Sell
6,480
-3,700
-36% -$315K 0.47% 35
2019
Q4 		$902K Sell
10,180
-583
-5% -$48.4K 0.61% 31
2019
Q3 		$815K Sell
10,763
-4,962
-32% -$340K 0.57% 30
2019
Q2 		$1.14M Sell
15,725
-703
-4% -$55.3K 0.8% 22
2019
Q1 		$1.32M Buy
16,428
+36
+0.2% +$2.94K 1% 18
2018
Q4 		$1.51M Buy
+16,392
New +$1.44M 1.18% 15

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Riverview Trust Company's ABBV Position: Q1 2026 in Review

Riverview Trust Company held its AbbVie (ABBV) position steady in Q1 2026 at 3,193 shares worth $694K. The position accounts for 0.86% of the portfolio, ranked #21.

Riverview Trust Company first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.51M in Q4 2018. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Riverview Trust Company held 3,193 shares of AbbVie worth $694K as of Q1 2026.
  • Riverview Trust Company left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.86% of Riverview Trust Company's portfolio in Q1 2026, its #21 holding.
  • Riverview Trust Company first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Riverview Trust Company's AbbVie position peaked at $1.51M in Q4 2018.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Riverview Trust Company's 13F filing for Q1 2026, filed 1 May 2026.